Assembly Bio appoints Gilead's Cihlar to board and moves HQ to South San Francisco

ASSEMBLY BIOSCIENCES, INC.

Appointed Tomas Cihlar, Ph.D., Gilead's SVP of Virology, to the Board effective December 7, 2023, per Investor Rights Agreement.
Dr. Cihlar will not receive compensation for his Board service.
Corporate headquarters relocated to Two Tower Place, 7th Floor, South San Francisco, CA 94080 effective December 1, 2023.
The appointment stems from the October 15, 2023 Investor Rights Agreement with Gilead.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tomas Cihlar

Board Member

ASMB · ASSEMBLY BIOSCIENCES, INC.

Effective: 2023-12-07
Filed: December 7, 2023, 6:59 PM ET

On December 7, 2023, the Board of Directors (the "Board") of Assembly Biosciences, Inc. (the "Company") appointed Tomas Cihlar, Ph.D., a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tomas Cihlar was appointed as Board Member at ASSEMBLY BIOSCIENCES, INC..

Action: appointed
Role: Board Member

Exact text from the filing

On December 7, 2023, the Board of Directors (the "Board") of Assembly Biosciences, Inc. (the "Company") appointed Tomas Cihlar, Ph.D., a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board.

View on SEC.gov

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-068794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.